Castle Biosciences Reports on Shareholder Vote Outcome

Ticker: CSTL · Form: 8-K · Filed: 2024-05-24T00:00:00.000Z

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

Related Tickers: CSTL

TL;DR

Castle Biosciences held a shareholder vote on 5/23, results are in.

AI Summary

Castle Biosciences, Inc. filed an 8-K on May 24, 2024, reporting on a matter submitted to a vote of its security holders on May 23, 2024. The filing details the outcome of this vote, which is a standard procedural update for the company.

Why It Matters

This filing provides transparency on the results of a shareholder vote, which can impact corporate governance and future strategic decisions for Castle Biosciences.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a shareholder vote, with no immediate financial or operational risks indicated.

Key Players & Entities

FAQ

What specific matter was submitted to a vote of Castle Biosciences' security holders?

The filing indicates that a matter was submitted to a vote of security holders on May 23, 2024, but the specific details of the matter are not elaborated upon in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on May 23, 2024.

What is the filing date of this 8-K report?

This 8-K report was filed on May 24, 2024.

What is the principal executive office address for Castle Biosciences, Inc.?

The principal executive offices of Castle Biosciences, Inc. are located at 505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546.

What is the IRS Employer Identification Number for Castle Biosciences, Inc.?

The IRS Employer Identification Number for Castle Biosciences, Inc. is 77-0701774.

Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-05-24 16:27:43

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 23, 2024, Castle Biosciences, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following matters and cast their votes as set forth below: Proposal 1. Election of Directors The Company's stockholders elected the two individuals listed below as Class II Directors, each to serve until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified. The final voting results are as follows: For Withhold Broker Non-Votes Daniel M. Bradbury 15,949,886 5,278,263 1,238,314 Rodney Cotton 21,110,989 117,160 1,238,314 Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: For Against Abstain 22,265,288 184,003 17,172 Proposal 3. Approval of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement relating to the Annual Meeting. The final voting results are as follows: For Against Abstain Broker Non-Votes 20,622,511 306,249 299,389 1,238,314

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CASTLE BIOSCIENCES, INC. By: /s/ Derek J. Maetzold Derek J. Maetzold President and Chief Executive Officer Date: May 24, 2024

View on Read The Filing